SOURCES SOUGHT
66 -- rocurement of one (1) QIAsymphony SP System or Equivalent
- Notice Date
- 6/15/2020 6:13:38 AM
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- NIH National Cancer Institute Rockville MD 20850 USA
- ZIP Code
- 20850
- Solicitation Number
- 75N91020Q00102
- Response Due
- 6/22/2020 8:00:00 AM
- Archive Date
- 07/07/2020
- Point of Contact
- Adam Hernandez, Phone: 2402765633
- E-Mail Address
-
adam.hernandez@nih.gov
(adam.hernandez@nih.gov)
- Description
- This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified small business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned business concerns that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract based on responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 334516 with a size standard of 1,000 employees is being considered. NCI may issue a request for quotation (RFQ) as a result of this Sources Sought Notice. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI�s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. 1.0 BRAND NAME OR EQUAL This requirement is for the procurement of the brand name or equivalent instrument described in section 4.0. The Federal Acquisition Regulation (FAR) provision FAR 52.211-6, Brand Name or Equal (AUG 1999) is applicable to this requirement. 2.0 BACKGROUND The Clinical Oncologic Molecular Pathology Sequencing Service (COMPASS) program in the Laboratory of Pathology (LP) located in the Cancer Center for Research (CCR) at the National Cancer Institute (NCI) is committed to advancing genomic research and offering genomic testing so that new treatments, therapies and therapeutics against cancer can be developed. The COMPASS program is developing large NGS panels, whole exome sequencing and whole transcriptome sequencing assays to identify genetic changes in clinical specimens from cancer patients who are being evaluated and/or treated by NCI�s Intramural program. The Molecular Diagnostics Laboratory, a part of COMPASS program, performs molecular testing to assist in the diagnosis of a variety of cancers. The laboratory develops tests that assist in pathologic diagnosis, predict prognosis, and identify potential targets for rational personalized therapies. The Molecular Diagnostics Laboratory is currently the only Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology approved clinical laboratory within the NCI certified for performing molecular oncology testing on materials from NIH patients. The lab extracts DNA and RNA from over 1500 FFPE tissue specimen, DNA from over 1000 blood, bone marrow or other liquid specimens. With increasing test requests from NIH clinical center, there is an immediate need for an automated DNA/RNA extraction system. 3.0 TYPE OF ORDER This is a Firm-Fixed-Price Purchase Order. 4.0 PRODUCT FEATURES/SALIENT CHARACTERISTICS The instrument shall: Be one instrument capable of automatically processing kits that cover an extensive range of starting materials and applications to increase laboratory efficiency, improve quality assurance, simplify preventive maintenance, and streamline of clinical workflow. Be a modular system with a built-in touch screen to reduce user error and easily track specimens. Be capable of sample preparation and purification of DNA and bacterial and viral nucleic acids from up to 1000 �l human whole blood, 400 �l buffy coat, 50 mg tissue (including Formalin-Fixed Paraffin-Embedded [FFPE] tissue), or 1 x 107 cells. The laboratory has an increasing number of FFPE tissue spe SYSTEMS SUPPORT MECH
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/654dd54967214eb2b89894b84e703557/view)
- Record
- SN05691698-F 20200617/200615230218 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |